What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To evaluate the effects of elritercept on hematological and clinical outcomes in patients with myelofibrosis receiving ruxolitinib.

December 8, 2025Blood

Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended Phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the Phase 2 restore trial

View Full Paper

Ask AI

Bookmark

To evaluate the effects of elritercept on hematological and clinical outcomes in patients with myelofibrosis receiving ruxolitinib.
Phase 2 open-label trial evaluating elritercept as monotherapy and in combination with ruxolitinib.
Patients classified as transfusion-dependent or non-transfusion-dependent based on RBC unit requirements.
Data reported focuses on patients receiving elritercept with ruxolitinib at the recommended Phase 2 dose.
30.4% of transfusion-dependent patients achieved RBC transfusion independence by week 24.
14.3% experienced a spleen volume reduction of ≥25%, and 19% had a ≥50% reduction in MF-SAF total symptom score at week 24.
Demonstrated clinically significant improvements in hemoglobin levels in most patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase 2 trial shows elritercept enhances hemoglobin levels and reduces anemia in myelofibrosis patients receiving ruxolitinib, suggesting therapeutic benefits.

Cite This Study

Rinaldi et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de47 https://doi.org/10.1182/blood-2025-909

View Full Paper

Ask AI

Bookmark

Implication

Phase 2 trial shows elritercept enhances hemoglobin levels and reduces anemia in myelofibrosis patients receiving ruxolitinib, suggesting therapeutic benefits.

Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended Phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the Phase 2 restore trial

Key Points

Discussion

Implication

Cite This Study

Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended Phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the Phase 2 restore trial

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider